NCT06220773View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy

PHASE3RecruitingINTERVENTIONAL
Enrollment

276

Participants

Timeline

Start Date

May 21, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Essential HypertensionType 2 Diabetes Mellitus
Interventions
DRUG

BR1019A

Subjects take the investigational products once a day for 12 weeks.

DRUG

BR1019B

Subjects take the investigational products once a day for 12 weeks.

DRUG

BR1019C

Subjects take the investigational products once a day for 12 weeks.

DRUG

BR1019A-1

Subjects take the investigational products once a day for 12 weeks.

DRUG

BR1019B-1

Subjects take the investigational products once a day for 12 weeks.

DRUG

BR1019C-1

Subjects take the investigational products once a day for 12 weeks.

Trial Locations (2)

Unknown

RECRUITING

Severance Hospital, Seoul

RECRUITING

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY

NCT06220773 - A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy | Biotech Hunter | Biotech Hunter